The fixed-combination preparation of timolol and latanoprost has been available in Europe since 2001. Evidence supporting its level of clinical efficacy has been slowly accumulating, with some studies suggesting clear benefit and others showing only a modest additional effect relative to its individual components. Studies demonstrating long-term protection of visual function are sparse and more work is required in this area. Several reports indicate that fixed-combination timolol/latanoprost is safe and well tolerated. Other similar combination products are now competing directly with fixed-combination timolol/latanoprost, and further comparative studies will be required to assess their relative merits.
1
Timolol and pilocarpine (Timpilo ® ), which became available in Europe in 1992, was the first true fixed combination, and timolol and dorzolamide (Cosopt ® ), launched in 1998, continues to be popular among glaucoma practitioners. 2 When it appeared in 1977, 3 timolol became the gold standard in IOP control, and remained so for nearly two decades. On its appearance in 1996, latanoprost, a prostaglandin F2α analogue, began to usurp timolol's dominant position as the first line in glaucoma management, and is now the world's best-selling glaucoma drug.
Studies reporting the efficacy of the concomitant use of these monotherapies led to the development of fixed-combination timolol/ latanoprost. 4, 5 The fixed combination of timolol and latanoprost, marketed as Xalacom ® in Europe, became commercially available in 2001 and was heralded by a series of short-term studies examining its efficacy, safety and tolerability. This article summarises the evidence to date on fixed-combination timolol/latanoprost and looks at the future for this fixed-combination glaucoma preparation.
Pharmacology and Function of Fixed-combination Timolol/Latanoprost
Fixed-combination timolol/latanoprost consists of 0.5% timolol as the isopropyl ester maleate and 0.005% latanoprost, a prodrug of a 17-phenyl substituted F2α analogue. The individual components have different modes of action in the control of IOP in humans. Latanoprost is highly selective for the FP receptor, one of several prostaglandin receptor sites in humans and primates, to increase uveoscleral outflow, 6 although there is some evidence that the conventional outflow pathway is also involved. 7 Its mode of action is thought to involve the induction of matrix metalloproteinases (MMPs) in the ciliary body smooth muscle and possibly also in ciliary melanocytes. [8] [9] [10] MMPs then break down the ciliary body extracellular matrix and reduce hydraulic resistance to uveoscleral outflow. Meanwhile, timolol acts at β-adrenergic receptors in the ciliary body to decrease production of aqueous humour, 11 but its exact mode of action remains unclear. study comparing the unfixed components given concomitantly in the morning and evening, compared versus timolol, gave greater daytime reduction with evening dosing and lower night-time pressures with morning dosing. 12 Latanoprost had previously been shown to produce a greater daytime ocular hypotensive effect when dosed at night. 13 Some variability may therefore be attributed to the fact that morning dosing of fixed-combination timolol/latanoprost occurred in some studies, 14, 15 while in others evening dosing was used. In a clinical study conducted in Glasgow, UK, a group of 59 patients switched from latanoprost monotherapy to fixed-combination timolol/latanoprost showed a mean reduction in IOP of 2.6mmHg. p=0.03). 25 Another trial investigated switching to a fixed-combination timolol/latanoprost from other therapies and showed that fixedcombination timolol/latanoprost was as effective as latanoprost used with a dorzolamide/timolol fixed-combination but only for the two-month duration of the study. Long 
Pressure-lowering Efficacy of Fixed-combination Timolol/Latanoprost
-term Efficacy and Safety of Fixed-combination Timolol/Latanoprost showed a pressure increment of between 1.5 and 2.9mmHg
Long-term Efficacy of Fixed-combination Timolol/Latanoprost
While it is known that timolol shows a 'drift' in its effect over time,
with IOP rising slowly after several years of use, 32 there are as yet no studies showing a corresponding latanoprost 'drift', 33 and evidence is emerging that the efficacy of the fixed combination may be retained in the longer term. Efficacy was maintained for one year in one study, 15 and a recent five-year study of the safety of fixedcombination timolol/latanoprost, the results of which have been presented in abstract form, suggested that the mean IOP reduction of 4.0mmHg varied only slightly over the five-year period. 34 Why should studies of the efficacy of fixed-combination timolol/ latanoprost produce apparently conflicting results? Inevitably, there is a rush to evaluate the new drug against its peers and this produces an almost bewildering variety of approaches and protocols. Large multicentre, randomised, double-blind studies may be considered to be the gold standard, but even these may not be completely free from bias or from phenomena such as the Hawthorne effect, whereby the performance of subjects (including compliance) improves simply by virtue of being included in a study.
Retrospective studies may be particularly prone to the effect of 'regression to the mean', which tends to exaggerate the impact of a particular intervention. 35 Another factor influencing variability may include the racial composition of the study population. 36 A pooled data analysis of eight clinical trials conducted in Asia, Europe and North and South America concluded that a greater difference in mean diurnal IOP reduction between latanoprost and timolol was seen in the Asian and Mexican patients than in the European and US patients. It was suggested that an apparently enhanced effect of latanoprost was associated with ethnic origin or eye colour differences. However, others have suggested that ethnicity has no influence on the effectiveness of latanoprost. 37 The results of 24-hour efficacy studies may also be affected by the tonometry technique employed. Nocturnal readings will vary depending on the position in which they are taken -seated or supine 38 -and evaluation of IOP may also be affected by hospitalisation, exposure to light during night-time measurements, disturbed sleep and sudden awakening. 39 The efficacy of evening dosing with timolol is dismissed by some researchers as negligible or non-existent, 40, 41 while others implicate this as an important contributor to night-time systemic hypotension and, thereby, disease progression. 27, 42 Those opposed to fixed combinations in general may cite the fact that they leave no scope for altering the amount of the individual components prescribed. Many clinicians prefer to retain the flexibility of being able to change the dose of timolol; for example, this would allow a patient to be administered a dose ranging from 0.25 to 0.5%, rather than being bound by the fixed combination's composition.
Visual Field Protection and Fixed-combination Timolol/Latanoprost
In the management of glaucoma, IOP lowering is merely a controllable surrogate for the ultimate goal of therapy, which is the prevention of the loss of visual function. Nevertheless, several landmark studies [43] [44] [45] [46] have shown that lowering IOP can reduce the risk of progression in glaucoma, with a fall in IOP of a single millimetre of mercury reducing the risk of progression by 10%. 45, 46 While the documented pressure- With respect to hyperaemia, this occurs less frequently with timolol than with latanoprost, 14, 15, 47 but latanoprost causes less ocular hyperaemia than the other prostaglandin analogues. 48 Timolol has well-known associated systemic effects such as bronchial spasm and bradycardia, and is contraindicated in bronchial asthma and severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second-or third-degree heart block, cardiac failure and
It is only eight years since fixedcombination timolol/latanoprost was launched, and during this time it has
established a good safety profile.
cardiogenic shock. 49 An oral beta-blocker taken at the same time can potentiate these cardiac effects.
The prostaglandin analogues have achieved notoriety for their association with iris and eyelid darkening and thickening and lengthening of the eyelashes. Darkening of the iris is thought to be due to an increase in the amount of melanin within a stable iris melanocyte population and is irreversible although entirely harmless. 6 However, one study has suggested that the iris pigmentation may be reversible on cessation of the drop. 50 Lengthening and thickening of the lashes is thought to occur least in latanoprost of all the prostaglandin analogues and is reversible on cessation of the drop. Patients often have a positive response to this change, although lashes may occasionally be so long as to interfere with spectacle wear and even accurate drop administration. 51 Early studies on fixed-combination timolol/latanoprost cited the occurrence of burning, conjunctival hyperaemia, ocular itching, tearing, dry eye, eyelid laxity, blurred vision, floaters, blepharitis, diplopia, sinus allergies 35 and even back pain. 52 Other more serious adverse events can include changes in refractive error, upper respiratory tract infection, cardiac failure, tachycardia, blood pressure or pulse rate changes and increased iris pigmentation. 14, 50 Patients were withdrawn from one study with finger and arm fractures. 13 Night-time use of a beta-blocker has been implicated as contributing to progression in some cases of glaucomatous optic neuropathy by the reduction of ocular perfusion pressure. 45 However, significant adverse effects appear to be very uncommon.
Glasgow Royal Infirmary's patient database provides 'real-life' data on patients being seen in clinics and suggests that fixed-combination timolol/latanoprost is among the best tolerated glaucoma medications, with only 8.6% of patients having to discontinue the drop due to adverse events. 53 A further study from the same database showed that fixed-combination timolol/latanoprost had the greatest persistency of use, with 64.2% of patients prescribed the preparation still using it at 60 months. 54 A large European five-year study looked at the incidence of iris pigmentation from baseline, darkening, lengthening and thickening of the eyelashes or pigmentation of periorbital skin and spontaneously reported adverse events or serious adverse events. 33 Presented in abstract form, this study, involving 974 patients, found that 42.6% of them developed overall increased iris pigmentation, 58.1% developed eyelash change and 5.2% developed peri-orbital skin changes. One patient developed cystoid macular oedema. Overall, this study concluded that, even after 60 months of treatment, fixed-combination timolol/latanoprost was safe and well tolerated for patients with primary open-angle glaucoma and ocular hypertension. This is believed to be the longest study to date examining these issues.
The Future for Fixed-combination Timolol/Latanoprost
It is only eight years since fixed-combination timolol/latanoprost was launched, and during this time it has established a good safety profile.
Although evidence of its efficacy in lowering IOP has at times been conflicting, the benefits it offers in terms of ease of compliance and reduced exposure to preservatives have confirmed it as a useful addition to the therapeutic armamentarium in many parts of the world. Following the introduction of other combination betaadrenergic receptor blocker/prostaglandin analogue products, such as fixed-combination travoprost/timolol and fixed-combination timolol/bimatoprost, as well as the adrenergic receptor blocker/ carbonic anhydrase timolol/brinzolamide fixed combination, the market for fixed-combination products is becoming more crowded.
Further high-quality comparative studies will be required to evaluate the long-term relative strengths and weaknesses of these products. n
